or Try an Advanced Search...

    Technical Analysis for ACXP - Acurx Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 2.14 -4.89% -0.11
    ACXP closed down 4.89 percent on Monday, July 1, 2024, on 47 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ACXP trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 50 DMA Bearish -4.89%
    Lower Bollinger Band Walk Weakness -4.89%
    Inside Day Range Contraction -4.89%
    Oversold Stochastic Weakness -4.89%
    20 DMA Resistance Bearish -7.36%
    Crossed Above 50 DMA Bullish -7.36%
    Stochastic Buy Signal Bullish -7.36%
    Expansion Pivot Buy Setup Bullish Swing Setup -7.36%
    Older End-of-Day Signals for ACXP ...

       Recent Intraday Alerts

    Alert Time
    Lower Bollinger Band Support about 5 hours ago
    Possible NR7 about 6 hours ago
    Down 3% about 9 hours ago
    Fell Below Previous Day's Low about 9 hours ago
    60 Minute Opening Range Breakout about 9 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ACXP Chart by TradingView
    Basic chart:

    Profile

    Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Health Care Antibiotics Bacterial Infections Staphylococcus Aureus Methicillin Gram Positive Bacteria Vancomycin

    Is ACXP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 6 New to The Street Announces Episode 576, Four Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, Thursday, June 6, 2024, at 9:30 PM PT
    May 16 Acurx Pharmaceuticals Inc (ACXP) Q1 2024 Earnings Call Transcript Highlights: Key Financial and ...
    May 16 Q1 2024 Acurx Pharmaceuticals Inc Earnings Call
    May 15 Acurx Pharmaceuticals, Inc. (ACXP) Q1 2024 Earnings Call Transcript
    May 15 Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
    May 15 Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
    May 15 Acurx Pharmaceuticals GAAP EPS of -$0.28 misses by $0.04
    May 2 Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
    Apr 25 Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
    Apr 23 Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update
    See more ACXP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.82
    52 Week Low 1.17
    Average Volume 48,870
    200-Day Moving Average 2.98
    50-Day Moving Average 2.27
    20-Day Moving Average 2.36
    10-Day Moving Average 2.26
    Average True Range 0.15
    RSI (14) 40.83
    ADX 15.24
    +DI 19.36
    -DI 18.91
    Chandelier Exit (Long, 3 ATRs) 2.15
    Chandelier Exit (Short, 3 ATRs) 2.60
    Upper Bollinger Bands 2.59
    Lower Bollinger Band 2.13
    Percent B (%b) 0.03
    BandWidth 19.64
    MACD Line -0.04
    MACD Signal Line -0.01
    MACD Histogram -0.03
    Fundamentals Value
    Market Cap 29.46 Million
    Num Shares 13.8 Million
    EPS -1.05
    Price-to-Earnings (P/E) Ratio -2.04
    Price-to-Sales 0.00
    Price-to-Book 10.74
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.31
    Resistance 3 (R3) 2.32 2.29 2.28
    Resistance 2 (R2) 2.29 2.24 2.28 2.27
    Resistance 1 (R1) 2.21 2.22 2.20 2.20 2.26
    Pivot Point 2.18 2.18 2.17 2.17 2.18
    Support 1 (S1) 2.10 2.13 2.09 2.09 2.02
    Support 2 (S2) 2.07 2.11 2.06 2.01
    Support 3 (S3) 1.99 2.07 2.00
    Support 4 (S4) 1.98